Novartis has welcomed a
recommendation by the Australian
Technical Advisory Group on
Immunisation that its Bexsero
meningitis B vaccine be used to
help protect young Australians,
with an emphasis on infants under
2 years of age and adolescents aged
between 15 and 19.
According to a statement issued
late yesterday inclusion of Bexsero
in the National Immunisation
Program is under consideration.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Mar 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.